On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation-Reference-Cited by-同舟云学术

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Published:2019-02-22 Issue:11 Volume:25 Page:3341-3351
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Brown Benjamin P.,Zhang Yun-Kai,Westover David,Yan Yingjun,Qiao Huan,Huang Vincent,Du Zhenfang,Smith Jarrod A.,Ross Jeffrey S.,Miller Vincent A.,Ali Siraj,Bazhenova Lyudmila,Schrock Alexa B.,Meiler Jens,Lovly Christine M.

Funder

NIH

NIHNCINCI

NRSA

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR by Newer 1-(3,5-Bis((E)-4‑hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies;Journal of Molecular Structure;2024-11

2. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

3. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

4. Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions;Frontiers in Oncology;2024-05-13

5. Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase;ChemMedChem;2024-05-03